References
- American College of Chest Physicians. Proceedings. Second ACCP Conference on Antithrombotic Therapy, June 21, 1988. Chest 1989: 95(2 Suppl): 1–169S
- Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1989: 95(2 Suppl): 2–4S
- Hirsh J. Treatment of pulmonary embolism. Annu Rev Med 1987: 38: 91–105
- Levine MN, Raakob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest 1989: 95(2 Suppl): 26–36S
- Gurwitz JH, Goldberg RJ, Holden A, et al. Age-related risks of long-term oral anticoagulant therapy. Arch Intern Med 1988: 148(8): 1733–6
- Wilcox CM, Truss CD. Gastrointestinal bleeding In patients receiving long-term anticoagulant therapy. Am J Med 1988: 84(4): 683–90
- Scandling J. Walker BK. Extensive tissue necrosis associated with warfarin sodium therapy South Med J 1980: 73(11): 1470–2
- Faraci PA. Deterling RA Jr, Stein AM, et al. Warfarin induced necrosis of the skin. Surg Gynecol Obstet 1978: 146(5): 695–700
- McGehee WG, Klotz TA, Epstein DJ, et al. Coumarin necrosis associated with hereditary protein C deficiency. Ann Intern Med 1984: 101 (1): 59–60
- Hirsh J, Levine M. Confusion over the therapeutic range for monitoring oral anticoagulant therapy in North America. Thromb Haemost 1988: 59(2): 129–32
- Hall R, Hirsh J, Jay R. et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982: 307(27): 1676–81
- Turpie AG. Gunstensen J, Hirsh J, et al. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988: 1(8597): 1242–5
- Hirsh J, Poller L. Deykin D, et al. Optimal therapeutic range for oral anticoagulants. Chest 1989: 95(2 Suppl): 5–11S
- Hyers TM. Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1989: 95(2 Suppl): 37–51S
- Escher JE, Gambert SR. Duthie EH. Anticoagulants and the elderly: a research dilemma. Age 1986: 9(3): 85–90
- Howard MR, Milligan DW. Frequency of attendance at anticoagulant clinics: a prospective study. BMJ (Clin Res) 1988: 296(6626): 898–9
- Howard MR, Milligan DW. Frequency of attendance at anticoagulant clinics. Acta Haematol (Basel) 1986: 76(2–3): 78–80
- Benollel R, Leviner E, Katz J, et al. Dental treatment for the patient on antlcoagulanttherapy: prothrombin time value—what difference does it make? Oral Suig Oral Med Oral Pathol 1986: 62(2): 149–51
- Katholi RE, Nolan SP, McGaire LB. Living with prosthetic heart valves: subsequent noncardiac operations and the risk of thromboembolism or hemorrhage. Am Heart J 1976: 92(2): 162–7
- Katholi RE, Nolan SP, McGaire LB. The management of anticoagulation during noncardiac operations In patients with prosthetic heart valves: a prospective study. Am Heart J 1978: 96(2): 163–5
- Tinker JH. Tarhan S. Discontinuing anticoagulant therapy In surgical patients with cardiac valve prostheses: observations in 180 operations. JAMA 1978: 239(8): 738–9
- Standing Advisory Committee for Haematology of the Royal College of Pathologists. Drug interaction with coumarin derivative anticoagulants. BMJ (CUn Res) 1982: 285(6337): 274–5
- Hansten PD, Horn, JR. Drug Interactions: clinical significance of drug-drug Interactions. 6th ed. Philadelphia: Lea & Febiger, 1989: 71–119